<DOC>
	<DOC>NCT00922597</DOC>
	<brief_summary>The objective of this international post-marketing surveillance study is to collect data on the efficacy and safety of continuous infusion with KOGENATE Bayer in surgery.</brief_summary>
	<brief_title>Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Inpatients with diagnosis of severe haemophilia A (FVIII &lt; 1%), heavily pretreated (&gt; 150 exposure days), without any history of inhibitors, a negative inhibitor test should be available, decision taken by the investigator to administer KOGENATE Bayer via continuous infusion during and after surgery.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Continuous infusion</keyword>
	<keyword>Surgery</keyword>
	<keyword>Severe haemophilia A</keyword>
</DOC>